

Xavier Garc a Del Muro Solans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/273237/publications.pdf>

Version: 2024-02-01

15
papers

727
citations

932766

10
h-index

940134

16
g-index

17
all docs

17
docs citations

17
times ranked

1267
citing authors

#	ARTICLE	IF	CITATIONS
1	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
2	Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103683.	2.0	12
3	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	0.8	108
4	Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. <i>Cancer Research</i> , 2021, 81, CT040-CT040.	0.4	8
5	Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. <i>Cancer Research</i> , 2021, 81, CT042-CT042.	0.4	10
6	Abstract CT187: Overall survival (OS) by response during "induction" from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC). <i>Cancer Research</i> , 2021, 81, CT187-CT187.	0.4	3
7	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
8	Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 452-460.	0.9	11
9	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5012-5012.	0.8	48
10	Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5097-TPS5097.	0.8	5
11	Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. <i>Sarcoma</i> , 2019, 2019, 1-14.	0.7	4
12	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144.	5.1	97
13	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	3.9	104
14	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. <i>Oncotarget</i> , 2018, 9, 17576-17588.	0.8	1
15	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA); Tj ETQq1 1 0.784314 rgBT /Overlook 5.1 49 2017, 18, 672-681a.	0.784314	49